What To Watch For In The Implementation Of FDA's Biosimilar Action Plan
Published By Biosimilar Development October 03, 2018

In July 2018, the FDA unveiled a Biosimilar Action Plan (BAP) intended to “facilitate the efficient development and approval” of biosimilar products. When FDA Commissioner Scott Gottlieb introduced the BAP, he emphasized the importance of building a market for biosimilar products and expressed concern that the market is not yet established.

Please click here to read more.